Retroperitoneal fibrosis

Retroperitoneal fibrosis (RPF) is a pathological process characterized by the formation of fibrous tissue in the retroperitoneal space. This condition can lead to compression of surrounding organs, including the kidneys, urinary tract, and, in some cases, large vessels, causing a range of clinical manifestations, including low back pain, urinary retention, and edema. RPF is most often associated with idiopathic factors, although it can also be caused by infections, inflammation, trauma, or the use of certain medications. The disease requires a careful approach to diagnosis and treatment, since inadequate intervention can lead to serious complications.

History of the disease and interesting historical facts

Retroperitoneal fibrosis was first described in the medical literature in 1905. At the beginning of the 20th century, this disease was considered rare and remained almost unknown to most physicians and surgeons. The etymology of the term "fibrosis" comes from the Latin word "fibra", meaning fiber, which indicates a pathological process associated with the proliferation of connective tissue in the retroperitoneal area. Major advances in the understanding of RPF occurred only in the 1970s, when the introduction of more sophisticated imaging techniques such as CT and MRI allowed for better visualization of fibrous tissue and the development of more objective diagnostic criteria. Notably, since the 1980s, some studies have begun to indicate a connection between RPF and certain medications, such as benzodiazepines and some anticancer drugs.

Epidemiology

Retroperitoneal fibrosis is a rare disease, with an incidence of 1-2 cases per 100,000 people per year. Men are affected twice as often as women, with a peak incidence between the ages of 50 and 70 years. Epidemiological data also indicate regional differences in incidence, requiring further research to determine possible environmental and genetic risk factors. Some epidemiological studies have noted that “secondary” RPF, resulting from comorbidities, is also described in medical records, making it more common among certain population groups.

Genetic predisposition to this disease

To date, no clear link has been established between genetic mutations and the development of retroperitoneal fibrosis. However, some studies indicate a possible predisposition to fibrotic processes in patients with a family history of connective tissue diseases. In particular, it has been found that certain groups of patients may have elevated levels of markers of inflammation and fibrosis, such as transforming growth factor beta (TGF-β), suggesting a possible genetic component. At the same time, questions about specific genes and molecular mechanisms remain open and require further study.

Risk factors for the development of this disease

Risk factors for the development of retroperitoneal fibrosis can be classified into physical and chemical, as well as based on other diseases. The main risk factors include:

• Chronic inflammatory diseases such as gout and kidney infections.
• Use of certain medications, including certain drugs used to treat high blood pressure and tumors.
• Exposure to toxic chemicals such as asbestos and some industrial solvents.
• Radiation treatment to the abdomen and pelvis.
• Age over 50 years, especially in men.

These factors may increase the risk of developing the disease, but the exact mechanisms remain poorly understood.

Diagnosis of this disease

Retroperitoneal fibrosis is diagnosed based on clinical manifestations, laboratory and radiological data. The main symptoms of RPF include:

• Pain in the lower back and/or abdomen.
• Urinary retention.
• Abdominal enlargement.
• General malaise and weight loss.

Laboratory tests may include:

• Complete blood count and biochemical parameters.
• Determination of levels of inflammation and fibrosis markers.

Radiological examinations such as CT and MRI play a key role in diagnosis, allowing to detect the presence of fibrous tissue and assess its extent. Other diagnostic methods may include puncture, in case of unclear findings. Differential diagnosis should exclude such conditions as kidney cancer, aortoarteritis and other tumor processes.

Treatment

Treatment of retroperitoneal fibrosis depends on the severity of the disease and the presence of complications. The main approaches to treatment include:

• Conservative treatment: observation, symptom control, use of corticosteroids to reduce fibrotic changes.
• Pharmacological treatment: use of immunosuppressants such as methotrexate and azathioprine.
• Surgical intervention: in cases where there is significant compression of organs or a threat to their functional activity, decompression operations can be used.
• Other methods: physical therapy and supportive therapy to improve quality of life.

List of medications used to treat this disease

The list of medications that may be prescribed to patients with retroperitoneal fibrosis includes:

• Corticosteroids (prednisolone, dexamethasone).
• Immunosuppressants (methotrexate, azathioprine).
• NSAIDs (ibuprofen, naproxen) for pain management.
• Inflammatory modulators (tofacitinib) in an investigational setting.

Disease monitoring

Monitoring of patients with retroperitoneal fibrosis includes regular visits to the doctor, ultrasound and radiological examination to assess the dynamics of the disease. The prognosis depends on timely diagnosis and adequate treatment. Possible complications include renal failure and deterioration of the function of other affected organs. It is important to monitor the patient's condition and monitor possible new symptoms.

Age-related features of the disease

Retroperitoneal fibrosis is most common in people over 50 years of age, due to age-related changes in connective tissue and a greater predisposition to chronic diseases. In older people, the disease may manifest itself with more sluggish symptoms and requires a cautious approach to diagnosis and treatment. In younger patients, RPF may be associated with other pathologies or exposure to chemicals, and its manifestations are usually more acute.

Questions and Answers

• What is retroperitoneal fibrosis? Retroperitoneal fibrosis is a disease characterized by the formation of fibrous tissue in the retroperitoneal space, which can lead to compression of surrounding organs.
• What are the main symptoms of retroperitoneal fibrosis? The main symptoms include lower back pain, urinary retention and general malaise.
• What diagnostic methods are used for retroperitoneal fibrosis? Diagnostics includes laboratory tests, CT and MRI, and, if necessary, puncture.
• How is retroperitoneal fibrosis treated? Treatment can be conservative (steroids, immunosuppressants) or surgical if organ decompression is necessary.
• What is the prognosis for patients with retroperitoneal fibrosis? The prognosis depends on the timeliness of diagnosis and treatment; serious complications are possible without adequate intervention.